ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

ORIC Pharmaceuticals announced a conference call and webcast for Friday, October 23, 2026, at 8:00 am ET to review enozertinib data being presented at the ESMO Congress 2026 in Madrid. The call will feature Dr. Joshua Sabari of NYU Grossman School of Medicine discussing enozertinib in first-line NSCLC patients with EGFR atypical mutations. ORIC will also present three posters at ESMO covering enozertinib and its PRC2 inhibitor rinzimetostat, including the global Phase 3 Himalayas-1 study in mCRPC.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.